Skip to content
buprenorphine

Structure via PubChem · Public domain (PubChem)

EntityQ407721· pop 40· linked from 1,472 articles

buprenorphine

Sign in to save

Also known as Buprenex®, Temgesic®, (-)-buprenorphine, 21-cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine, 2-(N-cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol, 17-cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol, 21-cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine, 2-(N-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol

Key facts

Drug.Verifiedfields
changed
Drug.Watchedfields
changed
Drug.verifiedrevid
457118559
Drug.image
Buprenorphine.svg
Drug.image_class
skin-invert-image
Drug.width
220
Drug.alt
Skeletal formula of buprenorphine
Drug.image2
Buprenorphine molecule from xtal ball.png
Drug.image_class2
bg-transparent
Drug.width2
220
Drug.alt2
Ball-and-stick model of the buprenorphine molecule
Drug.pronounce
bew-pre-nor-feen
Drug.tradename
Subutex, Sublocade, Belbuca, Brixadi, others
Drug.MedlinePlus
a605002
Drug.DailyMedID
Buprenorphine
Drug.pregnancy_AU
C
Drug.dependency_liability
Psychological: High Physical: Moderate
Drug.routes_of_administration
Sublingual, buccal, intramuscular, intravenous, transdermal, intranasal, rectal, subcutaneous

via Wikipedia infobox

Chemical data

Formula
C29H41NO4
Molecular weight
467.6 g/mol
IUPAC name
(1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
SMILES
C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O
InChIKey
RMRJXGBAOAMLHD-IHFGGWKQSA-N
XLogP
5
Polar surface area
62.2 Ų
H-bond donors
2
H-bond acceptors
5
Formal charge
0

via PubChem

Research

12,852 papers

via PubMed

~25 min read

Encyclopedic overview

31 sections
Contents
  • Medical uses
  • Opioid use disorder
  • Buprenorphine versus methadone
  • Chronic pain
  • Potency
  • Adverse effects
  • Respiratory effects
  • Buprenorphine dependence
  • Pain management
  • Pharmacology
  • Pharmacodynamics
  • Opioid receptor modulator
  • Other actions
  • Pharmacokinetics
  • Chemistry
  • Detection in body fluids
  • History
  • Society and culture
  • Regulation
  • United States
  • Europe
  • Barriers to access
  • Brand names
  • Research
  • Microdosing
  • Depression
  • Cocaine dependence
  • Neonatal abstinence
  • Veterinary use
  • References
  • External links

Buprenorphine, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection (intravenous and subcutaneous), as a skin patch (transdermal), or as an implant.

In the United States, the combination formulation of buprenorphine/naloxone (Suboxone) is usually prescribed to discourage misuse by injection. Maximum pain relief is generally within an hour with effects up to 24 hours. Buprenorphine affects different types of opioid receptors in different ways. Depending on the type of opioid receptor, it may be an agonist, partial agonist, or antagonist. Buprenorphine's activity as an agonist/antagonist is important in the treatment of opioid use disorder: it relieves withdrawal symptoms from other opioids and induces some euphoria (primarily when first starting treatment if one is not already opioid tolerant/dependent), but also blocks the ability for many other opioids, including heroin, to cause an effect. Unlike full agonists like heroin or methadone, buprenorphine has a ceiling effect, such that taking more medicine past a certain point will not increase the effects of the drug.

Excerpted from Wikipedia’s “buprenorphine” article, available under the CC BY-SA 4.0 licence.

Gallery (7)